Abstract: Objective To evaluate the adverse reaction and curative effect of simultaneous integrated boost conformal radiotherapy (SIB-CR) on patients with unresectable central non-small cell lung cancer(NSCLC). Methods Forty-four unresectable central NSCLC patients diagnosed histologically and cytologically from the Fourth Hospital of Hebei Medical University between Dec. 2007 to July 2013 were treated with SIBCR planning. The prescribed dose of PTV was 5 040cGy/28times(180cGy/time) and the dose for local tumor was 6 440cGy/28times(230cGy/time) simultaneously. The total treatment time was about 5.5 weeks (1 time a day, 5 times a week). The adverse reaction and curative effect were observed. Results The overall response rate(CR+PR) was 97.7% (43/44). The 1-, 2-, 3- and 5-years survival rates were 70.9%, 44.8%, 31.0% and 18.6% respectively. The 1-, 2-, 3- and 5-years local control rates were 93.8%, 63.9%, 58.1% and 58.1% respectively. The acute pneumonitis and esophagitis incidence rates were 29.6% and 25.0% respectively. The myelosuppression rate was 43.2%(19/44). Conclusion The SIB-CR technique for central NSCLC was feasible and with a high response rate. Radiation toxicities could be well tolerated. However, the long-term survival and late toxicities are still needed to be observed.